Measures daily activity and sleep in cancer patients entering early trials
Uses a wearable device to track activity and sleep in advanced cancer patients.
Plain-language title generated from the registry record
Registry title: APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials
Key facts
- Where
- Barcelona, Madrid, Pamplona, and Valencia, SpainSee the 5 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people with advanced cancer who have just agreed to join an early phase clinical trial and are willing to wear an activity device for 5-6 weeks.
- Age
- 16 years or older
- Sex
- All sexes can join
- Disease stage
- Advanced cancer; performance status ECOG 0 or 1
- Earlier treatment
- Must have consented to an early phase clinical trial
Main reasons for not taking part
- Unlikely to follow the study procedures and requirements, in the investigator's judgement
- Judged not able to enrol in an early phase clinical trial
Read by machine on 9 November 2026.
Where in Spain
- Vall d'Hebron Institute of Oncology (VHIO)Barcelona, SpainTaking people
- START Madrid - CIOCCMadrid, SpainNot yet recruiting
- START Madrid Fundación Jiménez Díaz (FJD) Quiron Salud HospitalMadrid, SpainNot yet recruiting
- Clínica Universidad de navarraPamplona, SpainTaking people
- Instituto de Investigacion Sanitaria, INCLIVAValencia, SpainTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Manchester
- Trial code
- NCT06868355
- Record updated
- 14 August 2025
- Original description
Increased physical activity has been shown to improve outcomes for cancer patients, however the measure of activity is highly variable and understudied in cancer patients on early phase clinical trials where activity is used as a criteria for eligibility. Additionally, more than half of cancer patients experience fatigue at some point in their treatment with exercise and psychosocial interventions currently recommended as interventions. Therefore, it is important to be able to more accurately measure activity and fatigue in cancer patients to ensure adequate intervention, management and appropriate access to treatment.Read full original descriptionShow less
APACE - Feasibility of Using Accelerometers to Measure Physical Activity in Cancer Patients on Early Phase Clinical Trials. A Feasibility Study Evaluating the Use of Accelerometers to Capture Physical Activity Levels in Cancer Patients on Early Phase Clinical Trials
Increased physical activity has been shown to improve outcomes for cancer patients, however the measure of activity is highly variable and understudied in cancer patients on early phase clinical trials where activity is used as a criteria for eligibility. Additionally, more than half of cancer patients experience fatigue at some point in their treatment with exercise and psychosocial interventions currently recommended as interventions. Therefore, it is important to be able to more accurately measure activity and fatigue in cancer patients to ensure adequate intervention, management and appropriate access to treatment.
This proposal is a non-interventional feasibility study designed to collect activity and sleep data from patients with advanced cancer newly enrolled in early phase clinical trials. The data will be collected over a 5-6 week period using a wearable accelerometer device. This study will be conducted concurrently with the early phase trial related activities/treatment and will have no impact on a patient's clinical pathway. Data generated from the study will be used to evaluate the feasibility of collecting activity and sleep data from patients with advanced cancer on early phase clinical trials.
In this study, participants in the UK will be able to opt-in to using eNutri, a web-based graphical food frequency questionnaire (FFQ), and provide feedback on its usability. The output of eNUTRI will help us understand if there is a use for eNutri in cancer care environments for a range of purposes such as providing nutritional support for cancer patients, and exploring drug-nutrient interactions on the patient outcome.
Inclusion: Voluntary informed consent; Aged at least 16 years; Consented to an early phase clinical trial; Willingness to wear a device for the duration of the study; Willingness to comply with scheduled study procedures; ECOG PS 0 or 1.
Exclusion: Judgement by the investigator that the individual should not participate if they are unlikely to comply with study procedures and requirements; Patient deemed ineligible for enrolment onto an early phase clinical trial.